Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Roche Holding AG
  6. Summary
    RO   CH0012032113

ROCHE HOLDING AG

(RO)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
01/18/2022 01/19/2022 01/20/2022 01/21/2022 01/24/2022 Date
392.8(c) 393.4(c) 390(c) 388(c) 370.2(c) Last
12 429 16 745 23 023 22 610 30 285 Volume
-1.01% +0.15% -0.86% -0.51% -4.59% Change
More quotes
Estimated financial data (e)
Sales 2021 62 399 M 68 168 M 68 168 M
Net income 2021 15 017 M 16 406 M 16 406 M
Net Debt 2021 7 316 M 7 992 M 7 992 M
P/E ratio 2021 19,1x
Yield 2021 2,87%
Sales 2022 62 398 M 68 167 M 68 167 M
Net income 2022 15 379 M 16 801 M 16 801 M
Net Debt 2022 3 045 M 3 327 M 3 327 M
P/E ratio 2022 17,9x
Yield 2022 3,05%
Capitalization 279 B 305 B 305 B
EV / Sales 2021 4,59x
EV / Sales 2022 4,52x
Nbr of Employees 101 465
Free-Float -
More Financials
Company
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The... 
Sector
Pharmaceuticals
Calendar
02/03 | 01:00amEarnings Release
More about the company
Ratings of Roche Holding AG
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about ROCHE HOLDING AG
01:01aGenentech's Evrysdi (risdiplam) Granted FDA Priority Review for Treatment of Pre-Sympto..
BU
01:00aRoche's Evrysdi (risdiplam) granted FDA priority review for treatment of pre-symptomati..
AQ
01/24US FDA Restricts Use of Eli Lilly, Regeneron's COVID-19 Treatments
MT
01/24Roche Says Data Show Faricimab Improved Vision in Final-Stage Studies
MT
01/24The Lancet publishes studies showing Roche's faricimab improved and maintained vision i..
AQ
01/24The Lancet Publishes Studies Showing Genentech's Faricimab Improved and Maintained Visi..
BU
01/24Chugai's Actemra Approved for Additional Indication of SARS-CoV-2 Pneumonia in Japan
AQ
01/24ROCHE HOLDINGS AG : JP Morgan remains Neutral
MD
01/20Credit Suisse Vice Chair Yet To Decide About Reelection At April Meeting
MT
01/20Credit Suisse Vice Chairman Unsure Whether He Will Stay on Board, Tages-Anzeiger Report..
DJ
01/20SEVERIN SCHWAN : Credit Suisse Vice-Chair Schwan undecided whether to stay on board -paper
RE
01/17ROCHE : virtual event on key ophthalmology data presented at the Angiogenesis 2022 Meeting
PU
01/17ROCHE HOLDINGS AG : Buy rating from Deutsche Bank
MD
01/17GMP production of CG01 made available for preclinical studies planned to enable First i..
AQ
01/13ROCHE HOLDINGS AG : JP Morgan gives a Neutral rating
MD
More news
News in other languages on ROCHE HOLDING AG
01/24Roche affirme que les données montrent que le faricimab améliore la vision dans les étu..
01/24ROCHE : études prometteuses autour du faricimab
01/24ROCHE : Genentech confirme l'efficacité de Faricimab (soins des yeux)
01/24Roche-Tochter Genentech bestätigt Wirksamkeit von Augenmittel Faricimab
01/24BOLSA DE MADRID : El mercado se enfrenta a sus demonios
More news
Analyst Recommendations on ROCHE HOLDING AG
More recommendations
Chart ROCHE HOLDING AG
Duration : Period :
Roche Holding AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ROCHE HOLDING AG
Short TermMid-TermLong Term
TrendsBearishBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Last Close Price 344,75 CHF
Average target price 404,97 CHF
Spread / Average Target 17,5%
EPS Revisions
Managers and Directors
Severin Schwan Chief Executive Officer & Executive Director
Alan Hippe Chief Financial & Information Officer
Christoph Franz Chairman
Pascale Schmidt Chief Compliance Officer
AndrÚ S. Hoffmann Vice Chairman
Sector and Competitors
1st jan.Capi. (M$)
ROCHE HOLDING AG-9.44%304 714
JOHNSON & JOHNSON-3.62%434 036
ROCHE HOLDING AG-4.87%319 830
PFIZER, INC.-10.60%296 303
ABBVIE INC.-2.53%233 325
ELI LILLY AND COMPANY-12.00%220 356